Treatment of Childhood Acute Lymphoblastic Leukemia in Different Risk Groups
スポンサーリンク
概要
- 論文の詳細を見る
Results of the Tohoku Children's Leukemia Study Group Protocol ALL 83 for treatment of 111 children with acute lymphoblastic leukemia according to risk group were reported. Patients at high risk (54 cases) had one or more of the following risk factors : age below two or above nine years, a initial white-cell count of 25, 000/μl or more, and the presence of T- or B-cell immunologic cell surface markers. All the other patients (57 cases) were in the standard-risk group. Patients in both the standard-risk and high-risk groups were treated for three years, receiving intensive multi-drug remission induction therapy, central nervous system prophylaxis, multidrug maintenance, and intensification therapy. At a median follow-up of 19 months, the mean (±SE) continuous complete remission rates at three years among the patients treated with Protocol 83-A, 83-B, and 83-C were 94±3%, 80±12%, and 69±9%, respectively. As compared with the previous Protocol ALL 78, this initial intensive multidrug regimen has resulted in improved disease-free survival in children with acute lymphoblastic leukemia.
- 特定非営利活動法人 日本小児血液・がん学会の論文
特定非営利活動法人 日本小児血液・がん学会 | 論文
- The Parent's Emotional Adaptation to the Children's Malignant Disease
- Side Effect of Cranial Radiation in Childhood Acute Leukemia
- Red Blood Cell Volume Distribution Width in Normal Children and in the Patients with Various Kinds of Hematological Disorders.
- Effective Conditioning of Donors for Granulocyte Transfusions with Recombinant Human Granulocyte Colony-Stimulating Factor.
- Two Infant Girls of CNS Leukemia with Chronic Subdural Hematoma